-
公开(公告)号:EP4458825A1
公开(公告)日:2024-11-06
申请号:EP22914529.7
申请日:2022-12-23
发明人: XI, Ning , LI, Xiaobo , LI, Minxiong , FENG, Xuejin
IPC分类号: C07D413/14 , A61K31/517 , A61P11/00 , A61P31/12 , A61P9/10 , A61P35/02 , A61P37/00
摘要: Provided are a salt of an aminopyrimidine compound and a use thereof. Specifically, provided are a salt of ( S )-2-(1-((6-amino-5-(3-methyl-1,2,4-oxadiazol-5-yl)pyrimidin-4-yl)amino)ethyl)-5-(3-hydroxypro p-1-yn-1-yl)-3-phenylquinazolin-4(3 H )-one and a pharmaceutical composition comprising the salt. Further provided is a use thereof in the preparation of a medicament for treating and preventing diseases related to PI3K kinase abnormalities.
-
公开(公告)号:EP4092025B9
公开(公告)日:2024-11-06
申请号:EP21741236.0
申请日:2021-01-15
发明人: YANG, Miao , SUN, Yuanyuan , LI, Wanjing , XU, Zhong , BAO, Pengyue , GAO, Jing , DONG, Ping , HUI, Hui , JI, Xiongfeng , LUO, Yunfu
IPC分类号: A61K9/00 , A61K9/10 , C07D471/04 , A61K31/519 , A61K31/517 , A61K9/72 , A61P11/08 , A61K47/26
-
公开(公告)号:EP4455133A1
公开(公告)日:2024-10-30
申请号:EP22910146.4
申请日:2022-12-22
发明人: YANG, Zhaohui , LIU, Songying , PAN, Jie , CHEN, Dong , XU, Ruo , MA, Liandong , TONG, Youzhi
IPC分类号: C07D401/14 , A61K31/4035 , A61K31/444 , A61K31/4427 , A61K31/4545 , A61K31/4523 , A61K31/506 , A61K31/515 , A61K31/4188 , A61K31/4196 , A61K31/343 , A61K31/517 , A61P35/00 , A61P31/00 , A61P31/18 , A61P31/14 , A61P31/20 , A61P37/00
摘要: Provided is a multi-protein degradation agent having an imide skeleton, which can degrade multiple proteins comprising c-Myc, GSPT1, CK1α and IKZF (1/2/3) proteins, and therefore can be used for treating diseases or disorders related thereto, such as cancer.
-
公开(公告)号:EP4452272A1
公开(公告)日:2024-10-30
申请号:EP22911443.4
申请日:2022-12-23
申请人: Astellas Pharma Inc.
发明人: NAGASHIMA, Takeyuki
IPC分类号: A61K31/517 , A61P1/00 , A61P11/00 , A61P35/00
-
公开(公告)号:EP4424379A3
公开(公告)日:2024-10-30
申请号:EP24184424.0
申请日:2020-03-11
申请人: CONVERGENE LLC , The United States of America, as represented by The Secretary, Department of Health and Human Services
发明人: YOSHIOKA, Makoto , YANG, Shyh-Ming , STROVEL, Jeffrey , MALONEY, David , JADHAV, Ajit , URBAN, Daniel Jason
IPC分类号: C07D413/14 , C07D471/04 , A61K31/517 , A61P11/00 , A61P35/00
摘要: The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.
-
公开(公告)号:EP4446325A1
公开(公告)日:2024-10-16
申请号:EP22903595.1
申请日:2022-12-09
发明人: TIAN, Jingwei , YE, Liang , LU, Jing , ZHANG, Jianzhao , LEI, Hui , BAI, Xinfa , WANG, Wenyan , ZHANG, Rui
IPC分类号: C07D487/04 , C07D487/14 , C07D491/048 , C07D495/04 , C07D495/14 , A61K31/517 , A61K31/519 , A61P35/00 , A61P37/00 , A61P25/00 , A61P31/12
摘要: The present invention relates to a series of compounds for regulating activity of a protein kinase, in particular a compound for inhibiting activity of PLK1. The present invention further provides a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition thereof in preparing a drug for preventing or treating diseases caused by and/or related to dysregulation of PLK1 kinase activity.
-
7.
公开(公告)号:EP4397317A3
公开(公告)日:2024-10-16
申请号:EP24170976.5
申请日:2018-08-30
IPC分类号: A61K31/4545 , A61P25/06 , A61K39/395 , A61K31/517
摘要: The present invention relates to combinations of lasmiditan and a calcitonin gene-related peptide (CGRP) antagonist such as rimegepant, ubrogepant, olcegepant, and MK-8031 and to methods of using the combinations for treatment of migraine, particularly migraine inadequately controlled by lasmiditan or a CGRP antagonist therapy alone, and more particularly, to treat therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment regimens.
-
公开(公告)号:EP3743075B1
公开(公告)日:2024-10-16
申请号:EP19743328.7
申请日:2019-01-22
发明人: QIN, Jun , FUKUDA, Koichi , VAYNBERG, Julia , RACHAKONDA, Suguna
IPC分类号: A61K31/517 , A61K31/5377 , A61K31/519 , A61K31/496 , C07D239/94 , A61P35/00 , A61K45/06 , A61P29/00
-
9.
公开(公告)号:EP4434982A1
公开(公告)日:2024-09-25
申请号:EP22912011.8
申请日:2022-12-23
申请人: LG Chem, Ltd.
发明人: LEE, Sung Bae , KIM, Chang Hoon , HUR, Jeong Mi , MOON, Hee Jeong
IPC分类号: C07D403/04 , A61K31/517 , A61K31/506 , A61K31/551 , A61P3/00 , A61P1/16 , C07D401/14 , C07D403/14 , C07D401/04 , C07D239/38
CPC分类号: A61K31/506 , A61K31/517 , A61K31/551 , A61P1/16 , A61P3/00 , C07D239/38 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
摘要: The present invention relates to a novel (S)-2-(2-methylazetidin-1-yl)pyrimidine derivative compound having ketohexokinase (KHK) inhibitory activity, a pharmaceutically acceptable salt thereof or an isomer thereof, and a pharmaceutical composition comprising same as active ingredients, and provides a compound of chemical formula 1, a pharmaceutically acceptable salt or isomer thereof, and a pharmaceutical composition containing same as active ingredients.
-
公开(公告)号:EP4417606A1
公开(公告)日:2024-08-21
申请号:EP22880399.5
申请日:2022-10-14
发明人: XIE, Hongming , LIU, Haiwang , ZHANG, Yingjun , JIA, Jinlong , FENG, Xihui
IPC分类号: C07D471/00 , C07D471/02 , C07D471/04 , C07D487/04 , C07D519/00 , C07D491/048 , A61K31/435 , A61K31/4375 , A61K31/517 , A61P35/00
CPC分类号: A61K31/435 , A61K31/4375 , A61K31/5377 , A61K31/517 , A61K31/519 , A61P35/00 , C07D471/00 , C07D471/02 , C07D471/04 , C07D487/04 , C07D491/048 , C07D519/00
摘要: A pyrimidopyridine compound, a pharmaceutical composition thereof, and a use thereof. Specifically, the present invention relates to a compound represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound represented by formula (I). The related compound and pharmaceutical composition thereof, as KRAS G12D inhibitors, can be used for preparing a drug for preventing or treating KRAS G12D-related diseases, especially for preparing a drug for preventing or treating cancer.
-
-
-
-
-
-
-
-
-